Metabolic Rewiring in Mutant Kras Lung Cancer

Overview

Journal FEBS J

Specialty Biochemistry

Date 2017 Jun 2

PMID 28570035

Citations 39

Authors

Emma M Kerr

Carla P Martins

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related death worldwide, reflecting an unfortunate combination of very high prevalence and low survival rates, as most cases are diagnosed at advanced stages when treatment efficacy is limited. Lung cancer comprises several disease groups with non small cell lung cancer (NSCLC) accounting for ~ 85% of cases and lung adenocarcinoma being its most frequent histological subtype. Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) affect ~ 30% of lung adenocarcinomas but unlike other commonly altered proteins (EGFR and ALK, affected in ~ 14% and 7% of cases respectively), mutant KRAS remains untargetable. Therapeutic strategies that rely instead on the inhibition of mutant KRAS functional output or the targeting of mutant KRAS cellular dependencies (i.e. synthetic lethality) are an appealing alternative approach. Recent studies focused on the metabolic properties of mutant KRAS lung tumours have uncovered unique metabolic features that can potentially be exploited therapeutically. We review these findings here with a particular focus on in vivo, physiologic, mutant KRAS activity.

Citing Articles

Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.

Xiang H, Kasajima R, Azuma K, Tagami T, Hagiwara A, Nakahara Y Front Immunol. 2024; 15:1361992.

PMID: 39735553 PMC: 11671776. DOI: 10.3389/fimmu.2024.1361992.

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.

Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.

PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.

A metabolomics study on carcinogenesis of ground-glass nodules.

Zhang X, Tong X, Chen Y, Chen J, Li Y, Ding C Cytojournal. 2024; 21:12.

PMID: 38628288 PMC: 11021118. DOI: 10.25259/Cytojournal_68_2023.

Variant Analysis of miRNA Regulatory Genes in 35 Sporadic Lung Carcinoma Tumors.

Bagci O, Ozdemir E, Sanliturk B Dokl Biochem Biophys. 2024; 513(Suppl 1):S1-S7.

PMID: 38472669 DOI: 10.1134/S1607672924600052.

Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.

Kim D, Min D, Kim J, Kim M, Seo Y, Jung B J Exp Clin Cancer Res. 2023; 42(1):338.

PMID: 38093368 PMC: 10720203. DOI: 10.1186/s13046-023-02922-8.

References

Svensson R, Parker S, Eichner L, Kolar M, Wallace M, Brun S . Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016; 22(10):1108-1119. PMC: 5053891. DOI: 10.1038/nm.4181. View

Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P . Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res. 2009; 7(8):1244-52. DOI: 10.1158/1541-7786.MCR-08-0532. View

Jackson E, Olive K, Tuveson D, Bronson R, Crowley D, Brown M . The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005; 65(22):10280-8. DOI: 10.1158/0008-5472.CAN-05-2193. View

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Yuneva M, Fan T, Allen T, Higashi R, Ferraris D, Tsukamoto T . The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012; 15(2):157-70. PMC: 3282107. DOI: 10.1016/j.cmet.2011.12.015. View

Prior I, Lewis P, Mattos C . A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012; 72(10):2457-67. PMC: 3354961. DOI: 10.1158/0008-5472.CAN-11-2612. View

Kerr E, Gaude E, Turrell F, Frezza C, Martins C . Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016; 531(7592):110-3. PMC: 4780242. DOI: 10.1038/nature16967. View

Frezza C, Martins C . From tumor prevention to therapy: empowering p53 to fight back. Drug Resist Updat. 2012; 15(5-6):258-67. DOI: 10.1016/j.drup.2012.10.001. View

10.

Jackson E, Willis N, Mercer K, Bronson R, Crowley D, Montoya R . Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001; 15(24):3243-8. PMC: 312845. DOI: 10.1101/gad.943001. View

11.

Vaughn A, Deshmukh M . Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol. 2008; 10(12):1477-83. PMC: 2626347. DOI: 10.1038/ncb1807. View

12.

Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H . ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008; 320(5876):661-4. DOI: 10.1126/science.1156906. View

13.

Cairns R, Harris I, Mak T . Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2):85-95. DOI: 10.1038/nrc2981. View

14.

Patra K, Wang Q, Bhaskar P, Miller L, Wang Z, Wheaton W . Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24(2):213-228. PMC: 3753022. DOI: 10.1016/j.ccr.2013.06.014. View

15.

Pollizzi K, Sun I, Patel C, Lo Y, Oh M, Waickman A . Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. Nat Immunol. 2016; 17(6):704-11. PMC: 4873361. DOI: 10.1038/ni.3438. View

16.

Feldser D, Kostova K, Winslow M, Taylor S, Cashman C, Whittaker C . Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010; 468(7323):572-5. PMC: 3003305. DOI: 10.1038/nature09535. View

17.

Schafer Z, Grassian A, Song L, Jiang Z, Gerhart-Hines Z, Irie H . Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009; 461(7260):109-13. PMC: 2931797. DOI: 10.1038/nature08268. View

18.

Gorrini C, Harris I, Mak T . Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12(12):931-47. DOI: 10.1038/nrd4002. View

19.

Bryant K, Mancias J, Kimmelman A, Der C . KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014; 39(2):91-100. PMC: 3955735. DOI: 10.1016/j.tibs.2013.12.004. View

20.

Porporato P, Sonveaux P . Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide. Mol Cell Oncol. 2016; 2(3):e968043. PMC: 4905283. DOI: 10.4161/23723548.2014.968043. View